Erin Doran

Robert Coleman, MD, discusses how relacorilant plus nab‑paclitaxel boosts survival in platinum‑resistant ovarian cancer.

Pelareorep plus FOLFIRI and bevacizumab showed durable responses in second-line RAS-mutant MSS metastatic colorectal cancer.

Dr Alexander Olawaiye discusses the impact of the FDA approval of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

The COMPANION-002 trial in biliary tract cancer allowed crossover to the tovecimig arm which likely confounded overall survival data.

The FDA has has granted a priority review to zanidatamab-based regimens for the first-line treatment of patients with gastroesophageal adenocarcinoma.

BBO-11818 has received FDA fast track designation for KRAS-mutant pancreatic cancer, with early phase 1 data showing antitumor activity.

Combination of interleukin-12 therapy with HAIP chemotherapy showed strong antitumor activity and manageable safety in metastatic CRC with liver metastases.

Enrollment restarts in a phase 2 ovarian and clear cell gynecologic cancer study after FDA lifts hold on PD-1/CTLA-4 DART therapy.

FDA reviews new zenocutuzumab bid for NRG1 fusion cholangiocarcinoma and NCCN adds new recommendations for use of the bispecific antibody.

Daraxonrasib nearly doubled median OS vs chemotherapy in pretreated metastatic pancreatic cancer, per phase 3 RASolute 302 trial data.

FDA grants fast track designation to SIM0505, a CDH6-targeting ADC, for platinum-resistant ovarian cancer. Phase 1 data expected at ASCO 2026.

Tovecimig plus paclitaxel lifts response rates in second-line biliary tract cancer, prompting FDA orphan status and advancing a potential new option.

FDA fast track status for CTIM-76 underscores the unmet need in platinum-resistant ovarian cancer.

New trial data show adding durvalumab/tremelimumab and lenvatinib to TACE delays progression in unresectable HCC, hinting at longer survival.

The oral FGFR2 inhibitor lirafugratinib is being reviewed by the FDA for the second-line treatment of cholangiocarcinoma harboring FGFR2 alternations.

ZW191 is engineered to bind to FRα, a cell-surface protein with high expression across several tumor types.

Final results from the phase 2 OVATION 2 trial show that adding IMNN-001 to standard chemotherapy significantly improves overall survival in newly diagnosed advanced ovarian cancer.

ATOMIC trial: adding atezolizumab to standard adjuvant chemotherapy cuts recurrence/death risk 50% in stage III dMMR colon cancer.

FDA backs pivotal phase 3 plan for VCN-01 plus chemo in metastatic pancreatic cancer, building on phase 2 VIRAGE trial success.

FDA pushes LNTH-2501 decision to June 2026 for manufacturing review.

Phase 1 data show HER2 ADC trastuzumab rezetecan drives responses in advanced gastric/GEJ and colorectal cancers with manageable safety and low ILD.